Characteristics of HPRT-mutant T cell lines in a lupus patient treated with cyclophosphamide

Arthritis Rheum. 1994 Oct;37(10):1548-52. doi: 10.1002/art.1780371021.

Abstract

This report describes T cell lines derived from a patient with subacute cutaneous lupus after treatment with intravenous pulse cyclophosphamide. We selected for mitotically active, hypoxanthine-guanine phosphoribosyltransferase-deficient (HPRT-) T cells, by culture in a selective medium containing 6-thioguanine. When HPRT- cell lines were derived 6 days after pulse cyclophosphamide (CYC) treatment, they were predominantly CD8+ and T cell receptor (TCR) gamma/delta+, producing interferon-gamma (IFN gamma). Cell lines derived 21 days after CYC treatment were CD4+, TCR alpha/beta+ and produced both IFN gamma and interleukin-4. These results support a possible role for gamma/delta+ T cells in subacute cutaneous lupus and suggest a mechanism for the therapeutic effect of CYC.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • CD4-Positive T-Lymphocytes / chemistry
  • CD4-Positive T-Lymphocytes / pathology*
  • CD8-Positive T-Lymphocytes / chemistry
  • CD8-Positive T-Lymphocytes / pathology*
  • Cell Line
  • Cyclophosphamide / administration & dosage*
  • Female
  • Humans
  • Hypoxanthine Phosphoribosyltransferase / deficiency*
  • Infusions, Intravenous
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / pathology*
  • Mutation
  • Receptors, Antigen, T-Cell / analysis

Substances

  • Receptors, Antigen, T-Cell
  • Cyclophosphamide
  • Hypoxanthine Phosphoribosyltransferase